{
    "clinical_study": {
        "@rank": "124344", 
        "arm_group": [
            {
                "arm_group_label": "metoprolol", 
                "arm_group_type": "Active Comparator", 
                "description": "patient or intervention group"
            }, 
            {
                "arm_group_label": "placebo group", 
                "arm_group_type": "Active Comparator", 
                "description": "control group"
            }
        ], 
        "brief_summary": {
            "textblock": "effect of B blocker was first evaluated in patient with cardiomyopathy not induced by\n      ischemia and idiopathic which as the most common causes of cardiomyopathy. Effect of BB on\n      Thalassemia cardiomyopathy was evaluated in this study"
        }, 
        "brief_title": "Effect of Metoprolol on Thalassemia Cardiomyopathy", 
        "completion_date": {
            "#text": "December 2012", 
            "@type": "Actual"
        }, 
        "condition": "B Thalassemia", 
        "condition_browse": {
            "mesh_term": [
                "Beta-Thalassemia", 
                "Thalassemia", 
                "Cardiomyopathies"
            ]
        }, 
        "detailed_description": {
            "textblock": "In this clinical trial, 45 patients with thalassemia cardiomyopathy were randomized to\n      receive either metoprolol (n = 26) or placebo (n = 19). Echocardiography and 6 minute walk\n      test was performed at baseline and repeated after 6 months and the values were compared."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  documented LVEF < 50% by echocardiography\n\n          -  B thalassemia\n\n          -  No decompensated heart failure for at least 4 weeks (hospitalization for CHF,\n             worsening lower extremity edema, worsening dyspnea on exertion, , and orthopnea)\n\n          -  have no evidence of acute myocarditis and\n\n          -  hemoglobin level above 7 gr\u2044dL.\n\n        Exclusion Criteria:\n\n          -  pulse rate below 60/min\n\n          -  systolic blood pressure less than 90 mmHg\n\n          -  evidence of peripheral vascular disease\n\n          -  major depression, history of asthma, PR interval more than 240 msec, second or third\n             degree AV block\n\n          -  major medical diseases including diabetes mellitus requiring insulin injection,\n             hypothyroidism, hypoparathyroidism, chronic renal failure (glomerular filtration rate\n             below 30 ml/min), hepatic cirrhosis, hepatitis-B and hepatitis-C, positive tests for\n             human immunodeficiency virus, and other hemoglobinopathies"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "25 Years", 
            "minimum_age": "13 Years"
        }, 
        "enrollment": {
            "#text": "45", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "May 18, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01863173", 
            "org_study_id": "91-3502"
        }, 
        "intervention": [
            {
                "arm_group_label": "metoprolol", 
                "description": "using B blocker in patient group", 
                "intervention_name": "metoprolol", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "placebo group", 
                "description": "placebo to control group", 
                "intervention_name": "placebo", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Metoprolol", 
                "Metoprolol succinate"
            ]
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "Thalassemia cardiomyopathy", 
            "metoprolol succinate", 
            "echocardiography", 
            "six minute walk test"
        ], 
        "lastchanged_date": "May 22, 2013", 
        "location": {
            "facility": {
                "address": {
                    "city": "Shiraz", 
                    "country": "Iran, Islamic Republic of", 
                    "state": "Fars"
                }, 
                "name": "Shiraz University of Medical Sciences"
            }
        }, 
        "location_countries": {
            "country": "Iran, Islamic Republic of"
        }, 
        "number_of_arms": "2", 
        "official_title": "The Effect of Metoprolol Succinate on the Cardiac Function of Patients With Thalassemia Cardiomyopathy a Double Blind Randomized Study", 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "iran:NIH", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 2/Phase 3", 
        "primary_completion_date": {
            "#text": "May 2012", 
            "@type": "Actual"
        }, 
        "primary_outcome": [
            {
                "description": "LV contractility", 
                "measure": "ejection fraction", 
                "safety_issue": "Yes", 
                "time_frame": "6 months"
            }, 
            {
                "description": "functional capacity", 
                "measure": "6 minutes walk test", 
                "safety_issue": "Yes", 
                "time_frame": "6 months"
            }, 
            {
                "description": "functional capacity", 
                "measure": "endsystolic volume", 
                "safety_issue": "Yes", 
                "time_frame": "6 months"
            }
        ], 
        "reference": [
            {
                "PMID": "16865210", 
                "citation": "Atiq M, Bana M, Ahmed US, Bano S, Yousuf M, Fadoo Z, Khurshid M. Cardiac disease in beta-thalassaemia major: Is it reversible? Singapore Med J. 2006 Aug;47(8):693-6."
            }, 
            {
                "PMID": "21055653", 
                "citation": "Murphy CJ, Oudit GY. Iron-overload cardiomyopathy: pathophysiology, diagnosis, and treatment. J Card Fail. 2010 Nov;16(11):888-900. doi: 10.1016/j.cardfail.2010.05.009. Epub 2010 Jul 3. Review."
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01863173"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Shiraz University of Medical Sciences", 
            "investigator_full_name": "Javad Kojuri", 
            "investigator_title": "professor", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "secondary_outcome": {
            "description": "drug complication,", 
            "measure": "patient compliance", 
            "safety_issue": "Yes", 
            "time_frame": "6 months"
        }, 
        "source": "Shiraz University of Medical Sciences", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Shiraz University of Medical Sciences", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "January 2012", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "May 2013"
    }
}